Annexon Stock

Annexon Equity

The The Equity of Annexon (ANNX) as of Aug 12, 2026 is 211.65 M USD. In the previous year, The Equity was 293.11 M USD — a change of -27.79% (lower).

Equity

211.65 MUSD

YoY

-27.79%

Last updated:

In 2026, Annexon's equity was 211.65 M USD, a -27.79% increase from the 293.11 M USD equity in the previous year.

Access this data via the Eulerpool API
Get Free API Key

Annexon Stock analysis

What does Annexon do? Annexon Inc is a biopharmaceutical company based in South San Francisco, California. It was founded in 2011 by Doug Love, Ted Love, and Arnon Rosenthal, who had previously worked at major pharmaceutical companies such as Genentech and Novartis. The company's main goal is to develop new treatment options for neurodegenerative diseases, focusing on the development of drugs that target the autophagy process in cells to reduce damage to nerve cells and alleviate symptoms. Annexon Inc has two divisions, Annexon Biosciences and Annexon Clinical, with partnerships with renowned pharmaceutical companies to advance drug development. Its main product is ANX005, a therapeutic antibody protein that targets the role of the complement system in neurodegenerative diseases. Annexon Inc has received multiple awards for its work and innovations and has a dedicated team of scientists and executives committed to improving the lives of people with neurodegenerative diseases. Annexon is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Annexon's Equity

Annexon's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Annexon's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Annexon's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Annexon's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Annexon’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Annexon stock

The Equity of Annexon is 211.65 M USD in 2026.

The Equity of Annexon changed from 293.11 M USD to 211.65 M USD, representing a -27.79% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Annexon since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Annexon historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Annexon

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Annexon